Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:20 PM
Ignite Modification Date:
2025-12-24 @ 12:20 PM
NCT ID:
NCT00090961
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed single, primary bronchogenic lung cancer
* Inoperable, locally advanced disease (unresectable stage IIIA OR stage IIIB disease)
* The following histologies are eligible:
* Adenocarcinoma
* Large cell carcinoma
* Squamous cell carcinoma
* Non-lobar and non-diffuse bronchoalveolar carcinoma
* Small cell lung cancer
* Must have received chemotherapy (platinum based) and radiotherapy for locally advanced unresectable lung cancer
* Must have achieved a complete response, partial response, or stable disease after treatment
PATIENT CHARACTERISTICS:
Age
* Not specified
Performance status
* Zubrod 0-2
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Cardiovascular
* No acute EKG changes, arrhythmia, or other cardiac abnormality that would preclude study participation
* No uncontrolled cardiac disease
* No recent myocardial infarction
Pulmonary
* Any FEV\_1 level by pulmonary function testing
Other
* Willing to participate in 12-week long exercise program
* Chemotherapy-induced neuropathy ≤ grade 2
* No uncontrolled diabetes mellitus
* No other medical condition that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* See Disease Characteristics
Endocrine therapy
* Not specified
Radiotherapy
* See Disease Characteristics
Surgery
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT00090961
Study Brief:
Protocol Section:
NCT00090961